Compare · NVO vs SKYE
NVO vs SKYE
Side-by-side comparison of Novo Nordisk A/S (NVO) and Skye Bioscience Inc. (SKYE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SKYE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $204.85B, about 8223.8x SKYE ($24.9M).
- Over the past year, NVO is down 34.2% and SKYE is down 75.5% - NVO leads by 41.3 points.
- NVO has hit the wire 3 times in the past 4 weeks while SKYE has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 8 for SKYE).
- Company
- Novo Nordisk A/S
- Skye Bioscience Inc.
- Price
- $45.89+6.25%
- $0.70-4.50%
- Market cap
- $204.85B
- $24.9M
- 1M return
- +1.81%
- -5.27%
- 1Y return
- -34.18%
- -75.49%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 3
- 0
- Recent ratings
- 25
- 8
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SKYE
- Skye Bioscience Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
- SEC Form 8-K filed by Skye Bioscience Inc.
- UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
- SEC Form 10-Q filed by Skye Bioscience Inc.
- Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
- SEC Form 3 filed by new insider Sharp John P
- SEC Form DEFA14A filed by Skye Bioscience Inc.
- SEC Form DEF 14A filed by Skye Bioscience Inc.
- Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit